The central obstacle is access: conventional antibodies are generally unable to reach intracellular targets. To overcome this, the team exploited the way cells naturally process proteins. When mutated KRAS(G12D is broken down, it can generate short protein fragments—neoantigens—that act as molecular “clues” for the immune system.

In many cases, such neoantigen fragments are loaded onto the cell surface for immune surveillance. The researchers focused on designing an antibody that can “read” one of these KRAS(G12D)-derived neoantigen fragments. Using a computational-to-experimental workflow, they selected candidates that would bind only to cancer cells presenting the relevant mutation-derived trace.

Their antibody is described as TCR-like, borrowing design logic from T-cell receptors, which recognize peptide fragments displayed on the major histocompatibility complex. In effect, the antibody provides an immunotherapy molecule with an analog of the T cell’s sensing mechanism, enabling it to distinguish cancer-associated intracellular mutations from normal cellular proteins.

Experimental tests showed that the antibody selectively binds KRAS(G12D)-bearing cancer cells while exhibiting minimal reactivity to non-mutant targets. Functional assays further indicated that the antibody can eliminate mutation-positive cancer cells in immunotherapy settings, supporting the concept that intracellular driver mutations can be made therapeutically visible.

Importantly, the study presents its platform as more than a single-mutation achievement. Because neoantigen generation is a general feature of mutated proteins, the same design strategy could be adapted to other cancer mutations that generate distinct intracellular fragments.

The research, led by Professor Byung-Ha Oh of KAIST’s Department of Biological Sciences with collaboration from Therazyne, was conducted by KAIST-affiliated investigators including SangPhil Ahn at Therazyne. The paper was published online in Molecular Therapy, reflecting the journal’s focus on gene and cell therapy innovations.

Overall, the study positions computational protein design paired with targeted screening as a route to next-generation precision antibody therapies. By aiming specificity at mutation-derived neoantigen signatures, the approach seeks to improve therapeutic discrimination and reduce collateral effects on healthy cells.

Subject of Research: TCR-like antibody targeting the KRAS(G12D) neoantigen (intracellular cancer mutation)
Article Title: Discovery of TCR-like antibodies to the KRAS G12D neoantigen via in silico-in vitro workflow
News Publication Date: 24-Jul-2026
Web References: http://dx.doi.org/10.1016/j.ymthe.2026.05.032
References: 10.1016/j.ymthe.2026.05.032
Image Credits: Credit: KAIST

Keywords: KRAS(G12D), neoantigen, TCR-like antibody, computational protein design, in silico-in vitro workflow, precision immunotherapy, intracellular targets, Molecular Therapy

The pancreas, a vital organ responsible for both endocrine and exocrine functions, harbors acinar cells that produce digestive enzymes. Dysregulation in these cells often sets the stage for the development of PanIN lesions, which if unimpeded, can evolve into invasive PDAC, a notoriously aggressive cancer with dismal prognosis. The oncogenic KRAS^G12D mutation is ubiquitously acknowledged as a central driver of pancreatic tumorigenesis; however, the modulatory role of key transcription factors like ATF3 in this context has remained elusive until now.

ATF3, or activating transcription factor 3, is part of the stress-responsive ATF/CREB family of transcription factors. It is rapidly induced under various physiological stresses and has been implicated in diverse cellular processes, ranging from apoptosis to cell cycle regulation. In pancreatic acinar cells expressing mutant KRAS^G12D, the functional role of ATF3 is particularly intriguing given its dual capacity to act as both a transcriptional activator and repressor, contingent upon cellular context.

By employing genetically engineered mouse models with acinar-specific deletion of ATF3 combined with KRAS^G12D activation, the research team meticulously delineated the landscape of transcriptional alterations. These models revealed a stark attenuation in PanIN lesion formation when ATF3 was absent, underscoring its pivotal role in facilitating KRAS-mediated neoplastic transformation of acinar cells.

Granular transcriptomic analyses uncovered that loss of ATF3 markedly restricted the breadth and magnitude of KRAS^G12D-driven transcriptional changes. This suggests that ATF3 acts as a critical mediator or co-factor, amplifying the oncogenic KRAS signaling cascade. Among the affected pathways were those governing cell proliferation, inflammation, and extracellular matrix remodeling—hallmarks of early pancreatic cancer development.

Intriguingly, ATF3 deficiency not only dampened KRAS-induced gene expression shifts but also appeared to stabilize acinar cell identity, a state often lost during the acinar-to-ductal metaplasia (ADM) process that precedes PanIN formation. This stabilization potentially blocks the cellular plasticity required for neoplastic progression, pointing towards a tumor-promoting role of ATF3 in this context.

This revelation challenges previous paradigms that broadly categorized ATF3 as a stress-induced protective factor. Instead, in the specific milieu of KRAS^G12D-mutant pancreatic acinar cells, ATF3 emerges as a facilitator of oncogenic transcription networks, thereby promoting early neoplastic lesion formation. This nuanced understanding redefines ATF3’s biological significance and invites reconsideration of its role in cancer biology.

Furthermore, the study underscores the therapeutic potential of targeting ATF3 or its downstream transcriptional partners to impede KRAS-driven pancreatic tumorigenesis. Given the current limitations in directly targeting mutant KRAS protein pharmacologically, modulating its transcriptional co-factors presents a promising alternative strategy to restrict tumor initiation and progression.

From a clinical perspective, early detection and interception of PanIN lesions are paramount for improving pancreatic cancer outcomes. The identification of ATF3 as a molecular switch governing KRAS-driven transcriptional reprogramming enhances the repertoire of biomarkers and molecular targets that could refine early diagnostic and therapeutic approaches.

The investigators also explored the epigenetic landscape accompanying ATF3 loss, illuminating changes in chromatin accessibility and histone modifications that correlate with suppressed oncogenic transcriptional activity. Such epigenetic insights deepen our comprehension of how transcription factors like ATF3 orchestrate complex genetic programs in neoplastic transformation.

This research contributes a vital piece to the complex puzzle of pancreatic carcinogenesis and illustrates the intricate crosstalk between oncogenic drivers and transcriptional regulators. It propels the field forward by elucidating a novel dependency of KRAS^G12D-induced pancreatic tumorigenesis on ATF3, fostering hope for more effective combinatorial therapeutic regimens in the future.

Importantly, the study’s design, leveraging tissue-specific genetic manipulations in vivo, provides a robust platform to interrogate context-dependent gene functions. This methodological approach serves as a blueprint for exploring other transcription factors implicated in cancer and underscores the necessity of cell-type specific investigations in the quest to fully understand tumorigenic processes.

As pancreatic cancer continues to represent a formidable clinical challenge, such fundamental discoveries are crucial in steering new research directions. Future work will need to elucidate the precise molecular interactome of ATF3 within KRAS-mutant acinar cells and potentially identify small molecules or biologics capable of modulating its activity.

In sum, this pioneering work reveals that acinar-specific ATF3 is not merely a passive bystander but an active participant in sculpting the oncogenic transcriptional landscape driven by KRAS^G12D mutations. Its loss impedes the transition of acinar cells toward pre-cancerous PanIN lesions, presenting an attractive target for early intervention in pancreatic cancer.

The implications of these findings extend beyond fundamental biology, offering a new conceptual framework for understanding how transcriptional dynamics intersect with oncogenic signaling in the pancreas. As therapeutic strategies evolve, targeting transcriptional co-factors such as ATF3 may become integral components of comprehensive pancreatic cancer management.

With pancreatic cancer projected to become an increasingly prevalent cause of cancer mortality globally, insights like these fuel optimism for breakthroughs that could transform patient outcomes by intercepting disease at its earliest—and most treatable—stages.

Subject of Research:
Role of activating transcription factor 3 (ATF3) in pancreatic acinar cells during KRAS^G12D-driven pancreatic intraepithelial neoplasia (PanIN) progression.

Article Title:
Acinar-specific loss of activating transcription factor 3 restricts KRAS^G12D mediated transcriptional changes and PanIN progression.

Article References:
Martin, M.B., Mousavi, F., Goebel, G. et al. Acinar-specific loss of activating transcription factor 3 restricts KRAS^G12D mediated transcriptional changes and PanIN progression. Cell Death Discov. 11, 503 (2025). https://doi.org/10.1038/s41420-025-02777-2

Image Credits: AI Generated

DOI: 10.1038/s41420-025-02777-2 (Published 06 November 2025)